Novo Nordisk continues to be a leader in the Indian insulin market. Novo Nordisk registered biotech revenue of 647.28 crore in 2011-12. With brands such as Levemir, NovoRapid, Novomix 30 and Victoza, Novo Nordisk continues to command more than half the share in the entire Indian insulin market. Novo Nordisk extended its Changing Diabetes in Children (CDiC) program to India. 12 CDiC clinics covering a total of10 Indian states will be established. Novo Nordisk Education Foundation signed an MoU with the Gujarat government to launch the Changing Diabetes Barometer Project. For market expansion, Novo Nordisk is tying up with different governments like Bihar and Gujarat for screening and awareness programs. It will continue to leverage its wide portfolio of insulins to maintain leadership. Novo Nordisk will maintain its existing production and marketing partnerships and look for partnering with local companies for research.
Performance:
Novo Nordisk has registered 40% growth in its revenues. Brands such as Levemir, NovoRapid, Novomix 30 and Victoza have a insulin market share of more than 60%.
BUSINESS: Insulin, growth hormone and hemostasis management products
Performance:
Novo Nordisk has registered 40% growth in its revenues. Brands such as Levemir, NovoRapid, Novomix 30 and Victoza have a insulin market share of more than 60%.
BUSINESS: Insulin, growth hormone and hemostasis management products
No comments:
Post a Comment